As of 2026-01-26, the EV/EBITDA ratio of Fulcrum Therapeutics Inc (FULC) is -10.27. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FULC's latest enterprise value is 534.71 mil USD. FULC's TTM EBITDA according to its financial statements is -52.05 mil USD. Dividing these 2 quantities gives us the above FULC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.1x - 11.3x | 8.7x |
| Forward P/E multiples | 13.3x - 15.5x | 14.6x |
| Fair Price | (11.96) - (10.00) | (10.36) |
| Upside | -211.2% - -193.0% | -196.4% |
| Date | EV/EBITDA |
| 2026-01-23 | -10.27 |
| 2026-01-22 | -10.59 |
| 2026-01-21 | -9.93 |
| 2026-01-20 | -10.12 |
| 2026-01-16 | -9.64 |
| 2026-01-15 | -9.89 |
| 2026-01-14 | -9.87 |
| 2026-01-13 | -9.75 |
| 2026-01-12 | -8.98 |
| 2026-01-09 | -9.34 |
| 2026-01-08 | -9.61 |
| 2026-01-07 | -9.47 |
| 2026-01-06 | -9.48 |
| 2026-01-05 | -10.37 |
| 2026-01-02 | -10.45 |
| 2025-12-31 | -10.86 |
| 2025-12-30 | -10.89 |
| 2025-12-29 | -11.56 |
| 2025-12-26 | -11.14 |
| 2025-12-24 | -11.58 |
| 2025-12-23 | -11.36 |
| 2025-12-22 | -12.38 |
| 2025-12-19 | -11.86 |
| 2025-12-18 | -11.74 |
| 2025-12-17 | -11.66 |
| 2025-12-16 | -12.09 |
| 2025-12-15 | -12.53 |
| 2025-12-12 | -12.61 |
| 2025-12-11 | -12.41 |
| 2025-12-10 | -13.45 |
| 2025-12-09 | -14.28 |
| 2025-12-08 | -12.60 |
| 2025-12-05 | -8.35 |
| 2025-12-04 | -8.20 |
| 2025-12-03 | -8.52 |
| 2025-12-02 | -8.40 |
| 2025-12-01 | -9.36 |
| 2025-11-28 | -10.47 |
| 2025-11-26 | -10.87 |
| 2025-11-25 | -11.10 |
| 2025-11-24 | -11.30 |
| 2025-11-21 | -10.84 |
| 2025-11-20 | -10.60 |
| 2025-11-19 | -11.06 |
| 2025-11-18 | -9.21 |
| 2025-11-17 | -9.13 |
| 2025-11-14 | -8.09 |
| 2025-11-13 | -8.24 |
| 2025-11-12 | -7.79 |
| 2025-11-11 | -7.57 |